Cilgavimab / Tixagevimab Side Effects

Medically reviewed by Drugs.com. Last updated on Nov 10, 2024.

Applies to cilgavimab / tixagevimab: intramuscular solution.

Important warnings This medicine can cause some serious health issues

Cilgavimab and tixagevimab is not currently authorized for use until further notice by the US Food and Drug Administration (FDA).

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Some side effects may occur during the injection. Tell your medical caregivers right away if you have:

• throat irritation, swelling in your face or throat;

• dizziness, a light-headed feeling (like you might pass out);

• chest pain, wheezing, shortness of breath;

• fever, chills, sweating, nausea;

• fast or slow heartbeats, headache, pounding in your neck or ears;

• weakness, tiredness;

• a rash or itching; or

• muscle pain.

Call your doctor if you have:

• confusion;

• weakness; or

• fast or slow heartbeats.

Also call your doctor at once, and get tested for COVID-19, if you develop any symptoms of COVID-19:

• fever, chills;

• cough, shortness of breath;

• tiredness;

• muscle or body aches;

• headache;

• sore throat;

• altered sense of taste or smell;

• stuffy or runny nose; or

• nausea, vomiting, or diarrhea.

Common side effects may include:

• headache;

• tiredness; or

• cough.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.

For healthcare professionals

Applies to cilgavimab / tixagevimab: intramuscular solution.

Cardiovascular adverse events

• Uncommon (0.1% to 1%): Serious cardiovascular events (including myocardial infarction, cardiac failure), serious thromboembolic events
• Frequency not reported: Cardiac serious adverse events, acute myocardial infarction, cardiac failure leading to death, sudden cardiac death^[Ref]

All patients who experienced cardiac serious adverse events had cardiac risk factors and/or history of cardiovascular disease at baseline.^[Ref]

Hypersensitivity

• Uncommon (0.1% to 1%): Hypersensitivity (included rash, urticaria)^[Ref]

Local

• Common (1% to 10%): Injection site reaction (included injection site pain, injection site erythema, injection site pruritus, injection site reaction, injection site induration)
• Frequency not reported: Injection-related reaction^[Ref]

Further information

Cilgavimab/tixagevimab side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer